Peptidomimetic Drugs

In May 2025, Researchers at the Indian Association for the Cultivation of Science (IASST) have highlighted the potential of peptidomimetic drugs—synthetic molecules that mimic natural neurotrophins—as a promising therapy for neurodegenerative diseases.

Key Points

ND Challenge: Neurodegenerative diseases (NDs) remain a global health burden, with limited effective treatment options.
Peptidomimetic Advantage: These synthetic molecules offer enhanced stability, brain permeability, and reduced immunogenicity, overcoming key limitations of natural neurotrophins.
Improved Targeting: Peptidomimetics can be engineered to bind more specifically to neuronal receptors, reducing side effects.
Drug Repurposing Potential: Researchers are also exploring the use of existing peptidomimetic drugs, including those for cancer, as candidates for treating NDs.
Future Outlook: With further development, peptidomimetic drugs could become a cornerstone therapy for Alzheimer’s, Parkinson’s, and other neurodegenerative disorders.